- Non-invasive prenatal testing (NIPT)
- Pre-implantation genetic screening (PGS)
- Pre-implantation genetic diagnosis (PGD)
- BRCA 1 & 2 panel
- Cancer hotspot panel
- Lung Cancer mutation panel
- RAS Extended Plus for Colorectal Cancer
- Thyroid cancer mutation profile
- AML mutation panel
- GIST mutation panel
- Prostate cancer mutation panel
- ABL1 TKI resistance mutations
- MPN mutations
- TP53 mutation
- GIST mutation panel
- IDH1 & IDH2 mutations for glioma
- KIT D816V mutation
- FGFR3 mutation for bladder cancer
- BCR-ABL detection
- PML-RARA detection
- ALL translocation panel
- AML translocation panel
- HLA typing
- Paternity testing
Lung Cancer mutation panel
Lung Cancer mutation panel
This test includes analysis of mutations of EGFR Exons 18-21 including EGFR T790M mutation, which is recommended in molecular testing guidelines for targeted treatment of lung cancer patients. Additionally the test also includes BRAF, KRAS, MET & RET mutations that are suggested to be performed if included as part of a larger panel if performed initially, or when routine EGFR, ALK, and ROS1 testing are negative*.
(*Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346)